ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Funding Mechanisms: How They Are Used

August 12, 1983

Cancer Centers Program To Implement Most Changes Sought By review Group

December 13, 1996

In Brief: NCI awards center Grant to Cancer Institute of New Jersey; Researcher Win Honors

April 4, 1997

Smoking Cessation Training Follows Doctors Into Practice

October 29, 2004

Black-White Disparity Seen In End Of Life Treatment

November 27, 2009

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004